Showing 2621-2630 of 7415 results for "".
- SGR Patch: AADA Disappointed By Congressional Actionhttps://practicaldermatology.com/news/20140401-sgr_patch_aada_disappointed_by_congressional_action/2459285/Statement from Brett M. Coldiron, MD, FAAD President, American Academy of Dermatology Association: The U.S. House of Representatives and Senate have averted a 24 percent cut in Medicare physician payments by agreeing to a one-year short-term measure (HR 4302) to maintain current Medicare payment r
- Alphaeon Acquires US License To Teoxane Laboratories' Dermal Fillers And Cosmeceutical Productshttps://practicaldermatology.com/news/20130802-alphaeon_acquires_us_license_to_teoxane_laboratories_dermal_fillers_and_cosmeceutical_products/2459484/Alphaeon Corporation, a wholly-owned subsidiary of Strathspey Crown Holdings, LLC, has acquired an exclusive US license for the full line of products from Teoxane Laboratories. Containing 100 percent non-animal origin, resorbable hyaluronic acid, Teoxane's dermal fillers are currently available in m
- New Jersey Passes Law Prohibiting Indoor Tanning for Those Under 17https://practicaldermatology.com/news/20130402-new_jersey_passes_law_prohibiting_indoor_tanning_for_those_under_17/2459575/The state of New Jersey recently passed a law that bans minors under the age of 17 years old from using indoor tanning devices. The law passed both the New Jersey House and Senate in February and was signed into law by Gov. Christopher Christie on April 1, 2013. Dirk M. Elston, MD, FAAD, President o
- Study Shows Poor Cardiovascular–Kidney–Metabolic Health Raises Risk of PsOhttps://practicaldermatology.com/news/poor-cardiovascularkidneymetabolic-health-raises-risk-of-pso/2475773/Adults with poor cardiovascular–kidney–metabolic (CKM) health face significantly higher risks of developing psoriasis and reduced life expectancy if diagnosed, new research reveals. The analysis of data from a large UK Bioba
- Analysis: New Biologics Account for 70% of Increased Medicare Dermatology Drug Spendinghttps://practicaldermatology.com/news/analysis-new-biologics-account-for-70-of-increased-medicare-dermatology-drug-spending/2475722/Spending on dermatology-related drugs under Medicare Part D nearly quadrupled between 2013 and 2022, with specialty medications (including biologics) responsible for the vast majority of that increase, according to a new study.
- Analysis Concludes No Single Preclinical Model Fully Mimics Human PsOhttps://practicaldermatology.com/news/Analysis-Concludes-No-Single-Preclinical-Model-Fully-Mimics-Human-PsO/2475576/Despite extensive preclinical model development, no single system fully mimics human psoriatic disease, according to a new analysis published in Expert Opinion on Drug Discovery. Researchers on the study emphasized the importance of preclinical models that can reproduce disease-re
- Study: Iron Oxide Formulation Improved Radiance in Melasma-Prone Skinhttps://practicaldermatology.com/news/study-feo-formulation-improves-radiance-in-melasma-prone-skin/2475517/A new study published in Journal of Drugs in Dermatology evaluated the incorporation of iron oxide (FeO) into a daily sun care routine could offer protection and any benefit for patients with melasma and photodamage.
- Meta-Analysis IDs Promising Therapies for Hidradenitis Suppurativahttps://practicaldermatology.com/news/meta-analysis-ids-promising-therapies-for-hidradenitis-suppurativa/2475515/A new network meta-analysis comparing treatments for moderate to severe hidradenitis suppurativa (HS) shows several agents offering significantly improved efficacy over placebo. Researchers reviewed phase 2 and 3 randomized c
- Aesthetic Management Partners Launches New Non-Surgical Skin Revitalization Systemhttps://practicaldermatology.com/news/aesthetic-management-partners-launches-new-non-surgical-skin-revitalization-system/2475272/Aesthetic Management Partners announced the launch of PLADUOpro, a dual argon and nitrogen gas plasma system designed for advanced skin restoration, earlier this month.
- Analysis: No Added MACE Risk With Ustekinumab in Psoriasis and PsAhttps://practicaldermatology.com/news/analysis-no-added-mace-risk-with-ustekinumab-in-psoriasis-and-psa/2475231/New research suggests no difference in the risk of major adverse cardiovascular events (MACE) among patients with psoriasis (PsO) and psoriatic arthritis (PsA) initiating ustekinumab compared to adalimumab, etanercept, or secukinumab.